GU Cancers Symposium

Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.

Minas P. Economides, MD, discusses the evolving role of biomarkers such as KIM-1 in refining risk stratification and highlighted emerging innovations that may reshape how kidney cancer is both imaged and therapeutically targeted.

Jonathan F. Anker, MD, PhD, discusses findings from the phase 2 HCRN GU 20-444 trial, evaluating a response-adapted, bladder-sparing approach using pembrolizumab monotherapy in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin chemotherapy.

Alexandra Drakaki, MD, discusses guidance from a modified Delphi panel on managing peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin.

Matthias Saar, MD, discusses findings from the phase 2 INDUCTA study, evaluating the use of inductive hormonal therapy to achieve operability in patients with T4 prostate cancer.

Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.

Daniel Shapiro, MD, FACS, discusses how emerging biomarker strategies and evolving combination therapies are reshaping risk stratification and treatment decision-making in kidney cancer.

Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer.

Matthew D. Galsky, MD, discusses the mechanism of action for FX-909, a first-in-class agent targeting PPARγ in advanced urothelial carcinoma.

Data from the CLIMATE trial indicate that detectable miR-371 post-orchiectomy is a marker of MRD in patients with clinical stage 1 testicular germ cell tumor.

Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.

Mark Farha, MD, BSc, MBA, discusses the development of a novel genomic score designed to predict early BCG failure in patients with non–muscle invasive bladder cancer.

Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.

Daniel J. George, MD, discusses results from a survey examining the experiences and unmet needs of caregivers supporting patients with metastatic prostate cancer.

Neal D. Shore, MD, FACS, shares key findings from a post hoc analysis of the EMBARK trial showing that sustained PSA responses are possible following only 9 months of treatment with enzalutamide plus leuprolide.

Sam S. Chang, MD, MBA, highlights 2 studies presented at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco, California, that he believes are particularly impactful for clinicians treating bladder cancer.

Robert J. Motzer, MD, discusses the scientific rationale for the LITESPARK-011 study, its design and key findings, and how this combination could potentially influence treatment strategies in renal cell carcinoma.

Mustafa J. Saleh, MD, highlights new research exploring whether germline-based polygenic risk scores could help predict outcomes for patients with kidney cancer.

Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.

Vignesh T. Packiam, MD, reviews several bladder cancer studies from ASCO GU 2026 that he described as clinically meaningful for practicing urologists.

Chad Tang, MD, discusses the development of a prognostic model—K-COMPASS—for patients with oligometastatic clear cell renal cell carcinoma.

FX-909, a first-in-class PPARγ inverse agonist, demonstrated manageable toxicity and preliminary antitumor activity in patients with advanced urothelial carcinoma.

Robert S. Svatek, MD, discusses the background and key findings from the SWOG S1602 trial, evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve NMIBC.

"The CR rates in both arms are compelling, being higher than 50% with both strategies…BI-EFS rates in participants at week 18 CR assessment were comparable between arms and were higher than 80% in both arms," said Andrea Necchi, MD.

Toni K. Choueiri, MD, discusses the background and key findings from the phase 3 LITESPARK-022 trial.

"Belzutifan plus lenvatinib addresses an unmet clinical need and represents a potential new treatment option for patients with RCC that progressed after PD 1 or-L1 therapy,” said Robert J. Motzer, MD.

David R. Wise, MD, PhD, highlights initial findings from a phase 1b study of pasritamig plus docetaxel in patients with metastatic castration-resistant prostate cancer.

“After 28 months’ follow-up, the combination of pembrolizumab and belzutifan resulted in a statistically significant and clinically meaningful improvement in disease-free survival over pembrolizumab single agent,” said Toni K. Choueiri, MD.

“When we looked at ctDNA dynamics, patients who had baseline and postneoadjuvant ctDNA negativity had the best outcomes," said Pooja Ghatalia, MD.